Contraline Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 31

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $92.5M

  • Investors
  • 69

Contraline General Information

Description

Developer of a male contraceptive product designed to provide non-surgical and reversible birth control procedures. The company's technology implants a non-hormonal, non-surgical, and reversible polymer hydrogel into the vas deferens for contraception and acts as a semi-permeable membrane, blocking sperm while allowing fluids through, enabling users to get a cost-effective approach to contraception effectively.

Contact Information

Website
www.contraline.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 818 East Jefferson Street
  • Suite 201
  • Charlottesville, VA 22902
  • United States
+1 (434)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • 818 East Jefferson Street
  • Suite 201
  • Charlottesville, VA 22902
  • United States
+1 (434)

Contraline Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Contraline Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
15. Later Stage VC (Series B) 17-Jun-2026 $92.5M Completed Clinical Trials - Phase 2
14. Secondary Transaction - Private Completed Clinical Trials - Phase 2
13. Accelerator/Incubator 01-Jan-2025 Completed Clinical Trials - Phase 2
12. Later Stage VC (Series B) 05-Apr-2022 Completed Clinical Trials - General
11. Later Stage VC (Series A1) 20-Oct-2021 Completed Clinical Trials - General
10. Grant 18-Nov-2020 Completed Pre-Clinical Trials
9. Debt - PPP 17-Jul-2020 Completed Pre-Clinical Trials
8. Seed Round 18-Sep-2018 Completed Startup
7. Seed Round 18-Apr-2017 $2.25M $3.01M Completed Startup
6. Grant 13-Jun-2016 $50K $755K Completed Startup
To view Contraline’s complete valuation and funding history, request access »

Contraline Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B1
Series B5
Series B4
Series B3
Series B2
Series A3
Series A2 686,858 $0.001000 $3.41 $3.41 1x $3.41 3.53%
Series A1 1,870,371 $0.001000 $4.89 $4.89 1x $4.89 9.62%
To view Contraline’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Contraline Patents

  • 63

    Total Documents Applications and Grants

  • Total Patents Families

  • 28

    Granted

  • 15

    Pending

  • Expiring in next 12 mo

Contraline Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026060107-A1 Compositions and methods for male contraception Pending 11-Sep-2024
AU-2024370669-A1 Aerogel implants for contraception Pending 01-Nov-2023
EP-4801578-A1 Aerogel implants for contraception Pending 01-Nov-2023
US-20250134702-A1 Aerogel implants for contraception Pending 01-Nov-2023
WO-2025097044-A1 Aerogel implants for contraception Inactive 01-Nov-2023 A61F6/225
To view Contraline’s complete patent history, request access »

Contraline Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Contraline Investors (69)

Investor Name Investor Type Holding Investor Since Participating Rounds
Adage Capital Management Hedge Fund Minority
Aurum Venture Partners Venture Capital Minority
BVF Partners Hedge Fund Minority
Cleo Capital Venture Capital Minority
Convergent Ventures (San Francisco) Venture Capital Minority
You’re viewing 5 of 69 investors. Get the full list »

Ready to get started?

Request a free trial

Contraline FAQs

  • When was Contraline founded?

    Contraline was founded in 2015.

  • Where is Contraline headquartered?

    Contraline is headquartered in Charlottesville, VA.

  • What is the size of Contraline?

    Contraline has 31 total employees.

  • What industry is Contraline in?

    Contraline’s primary industry is Drug Discovery.

  • Is Contraline a private or public company?

    Contraline is a Private company.

  • What is the current valuation of Contraline?

    The current valuation of Contraline is .

  • What is Contraline’s current revenue?

    The current revenue for Contraline is .

  • How much funding has Contraline raised over time?

    Contraline has raised $116M.

  • Who are Contraline’s investors?

    Adage Capital Management, Aurum Venture Partners, BVF Partners, Cleo Capital, and Convergent Ventures (San Francisco) are 5 of 69 investors who have invested in Contraline.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process